Regencell Bioscience (NASDAQ:RGC) Shares Up 8.7% – What’s Next?

Regencell Bioscience Holdings Limited (NASDAQ:RGC) shares traded up 8.7% during trading on Tuesday. The stock traded as high as $7.06 and last traded at $7.3490. Approximately 101,532 shares traded hands during mid-day trading, a decline of 66% from the average session volume of 299,003 shares. The stock had previously closed at $6.76.

Analyst Ratings Changes

Several brokerages recently commented on RGC. Weiss Ratings reiterated a “sell (e+)” rating on shares of Regencell Bioscience in a research report on Monday, September 21st. Wall Street Zen lowered Regencell Bioscience from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. One research analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Regencell Bioscience Stock Performance

The stock’s 50 day moving average is $6.70 and its two-hundred day moving average is $17.98.

Regencell Bioscience (NASDAQ:RGC) last released its quarterly earnings data on Wednesday, October 7th. The company reported ($0.01) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On Regencell Bioscience

An institutional investor recently bought a new stake in Regencell Bioscience stock. Amundi acquired a new stake in shares of Regencell Bioscience Holdings Limited (NASDAQ:RGC) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 8,595 shares of the company’s stock, valued at approximately $219,000. 0.13% of the stock is owned by hedge funds and other institutional investors.

Regencell Bioscience Company Profile

Regencell Bioscience Holdings Limited is a Hong Kong-based biotechnology company focused on developing traditional Chinese medicine (TCM) formulations for neurological and neurocognitive disorders. Its research has primarily targeted attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD), conditions for which the company is exploring TCM-based therapeutic approaches.

The company’s development activities center on proprietary herbal formulations and related treatment protocols.